Why Shattuck Labs Stock Flew Nearly 5% Higher on Friday
2026-07-24 22:07
•Eric Volkman •The Motley Fool
•• •••••••••• Axe Capital view
Why Shattuck Labs Gained Nearly 5% on Analyst Upgrade
JPMorgan’s upbeat stance on Shattuck Labs sparked a near 5% rally, lifted by positive drug trial data.
Shattuck Labs’ stock jumped following JPMorgan’s initiation of coverage with a strong buy rating, based on its lead drug candidate for inflammatory bowel disease. The new drug, SL-325, apparently shows better safety and effectiveness than competitors — a big deal in biotech where trial setbacks are common. For South African investors, this isn’t a direct JSE story, but it highlights the kind of clinical proof that can move stocks sharply, something to remember when eyeing local healthcare plays or even Naspers and Prosus, which dabble in global tech and healthcare innovations. The rand (USD/ZAR) might remain steady since the move is biotech-specific and unlikely to shake broader markets. Still, biotech stocks carry high risk; Phase 2 trials can fail or face delays, wiping out enthusiasm quickly. this is just my opinion and not financial advice
I’d watch Shattuck for now, given the promising data, but stay cautious until Phase 2 results. In South Africa, stick with well-established counters like Aspen or look at Naspers/Prosus for their tech exposure instead.
- USD/ZAR
- Prosus
- Phase 2 trial failure
- Broader biotech sector volatility
4/10
Shattuck Labs stock rose nearly 5% on Friday following JPMorgan Chase analyst Brian Cheng's initiation of coverage with an 'overweight' rating and $10 price target (35% upside). The bullish call was driven by positive clinical trial data for the company's lead drug candidate SL-325, a first-in-class antagonist antibody for inflammatory bowel disease, which showed a cleaner safety profile and stronger target engagement than competitors. The drug is scheduled to enter Phase 2 trials in Q3.
This article was originally published by The Motley Fool and has been adapted here for Axe Capital Trading News.
Publisher: The Motley Fool
Author: Eric Volkman
Categories: Healthcare, Equities
Tickers: STTK, AMJB, JPM, JPMPC, JPMPD, JPMPJ, JPMPK, JPMPL, JPMPM, VYLD
Sentiment: Positive - New analyst initiation with 'overweight' buy rating and 35% price target upside. Positive clinical trial data for lead drug candidate showing strong safety profile and target engagement. Stock rallied nearly 5% on the news. Mentioned as the source of the analyst report initiating coverage. No direct impact on JPMorgan's business; noted as advertising partner with disclosure.
Keywords: biotech, drug development, clinical trials, analyst coverage, SL-325, inflammatory bowel disease, Phase 2 trial
Insights:
- STTK: Positive: New analyst initiation with 'overweight' buy rating and 35% price target upside. Positive clinical trial data for lead drug candidate showing strong safety profile and target engagement. Stock rallied nearly 5% on the news.
- AMJB: Neutral: Mentioned as the source of the analyst report initiating coverage. No direct impact on JPMorgan's business; noted as advertising partner with disclosure.
- JPM: Neutral: Mentioned as the source of the analyst report initiating coverage. No direct impact on JPMorgan's business; noted as advertising partner with disclosure.